Addition of metformin to sildenafil treatment for erectile dysfunction in eugonadal nondiabetic men with insulin resistance. A prospective, randomized, double-blind pilot study

Journal of Andrology

Volumn 33, Issue 4, 2012, Pages 608-614

  Rey Valzacchi, Gastó N J ^a   Costanzo, Pablo R ^a   Finger, Luis A ^a   Layus, Alberto O ^a   Gueglio, Guillermo M ^a   Litwak, Leó N E ^a   Knoblovits, Pablo ^a  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

Erectile dysfunction; Insulin resistance; Male sexual function; Metformin; Sildenafil

Indexed keywords

METFORMIN; PLACEBO; SILDENAFIL;

ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; BLOATING; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ERECTILE DYSFUNCTION; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN RESISTANCE; INTERNATIONAL INDEX OF ERECTILE FUNCTION 5; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

AGED; DOUBLE-BLIND METHOD; ERECTILE DYSFUNCTION; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; MODELS, BIOLOGICAL; PENILE ERECTION; PILOT PROJECTS; PIPERAZINES; PURINES; SULFONES;

EID: 84866410536     PISSN: 01963635     EISSN: 19394640     Source Type: Journal    
DOI: 10.2164/jandrol.111.013714     Document Type: Article

References (39)

1. Aljada A, Dandona P. Effect of insulin on human aortic endothelial nitric oxide synthase. Metabolism. 2000;49:147-150.
2. Bansal TC, Guay AT, Jacobson J, Woods BO, Nesto RW. Incidence of metabolic syndrome and insulin resistance in a population with organic erectile dysfunction. J Sex Med. 2005;2:96-103.
3. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev. 1985;6:45-86.
4. Cersosimo E, De Fronzo R. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev. 2006;22:423-436.
5. Chang SC, Chen KK, Chang LS. Evaluation of erectile dysfunction using the International Index of Erectile Function-5 (IIEF-5) in 200 urological patients. J Urol ROC. 2000;11:108-113.
6. Corona G, Mannucci E, Petrone L, Schulman C, Balercia G, Fisher AD, Chiarini V, Forti G, Maggi M. A comparison of NCEPATPIII and IDF metabolic syndrome definitions with relation to metabolic syndrome-associated sexual dysfunction. J Sex Med. 2007;4:789-796.
7. Costanzo P, Knoblovits P, Rey Valzacchi G, Gueglio G, Layus O, Litwak L. Erectile dysfunction is associated with a high prevalence of obesity and metabolic syndrome. Rev Argent Endocrinol Metab. 2008;45:142-148.
8. De Jager J, Kooy A, Lehert P, Bets D, Wulffelé MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJ, Stehouwer CD. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med. 2005; 257:100-109.
9. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006;295:1288-1299.
10. Florez H, Luo J, Castillo-Florez S, Mitsi G, Hanna J, Tamariz L, Palacio A, Nagendran S, Hagan M. Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. Postgrad Med. 2010;122:112-120.
11. Garcia-Estevez DA, Araujo-Vilar D, Fiestras-Janeiro G, Saavedra-Gonzalez A, Cabezas-Cerrato J. Comparison of several insulin sensitivitiy indices derived from basal plasma insulin and glucose levels with minimal model indices. Horm Metab Res. 2003;35:13-17.
12. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol. 1999;83:25F-29F.
13. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf. 1999;20:489-503.
14. Hsueh WA, Quinones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardiol. 2003;92:10J-17J.
15. Jeremy JY, Angelini GD, Khan M, Mikhailidis DP, Morgan RJ, Thompson CS, Bruckdorfer KR, Naseem KM. Platelets, oxidant stress and erectile dysfunction: an hypothesis. Cardiovasc Res. 2000;46:50-54.
16. Jones RW, Rees RW, Ralph D, Persad RA, Jeremy JY. Oxygen free radicals and the penis. Expert Opin Pharmacother. 2002;3:889-897.
17. Katz A, Nambi SS, Mather K, Baron AD, Follman DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402-2410.
18. Kim YW, Park SY, Kim JY, Huh JY, Jeon WS, Yoon CJ, Yun SS, Moon KH. Metformin restores the penile expression of nitric oxide synthase in high-fat-fed obese rats. J Androl. 2007;28:555-560.
19. Knoblovits P, Costanzo PR, Rey Valzacchi GJ, Gueglio G, Layus AO, Kozak AE, Balzaretti MI, Litwak LE. Erectile dysfunction, obesity, insulin resistance, and their relationship with testosterone levels in eugonadal patients in an andrology clinic setting. J Androl. 2010;31:263-270.
20. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone binding-globulin, total testosterone and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab. 2006;91:843-850.
21. Litwak LE, Graffigna MN, Abdala MM, Akel ME, Aranda C, Gutt S, Levalle O, Marcial Toro J, Migliano M, Pérez de la Puente M, Pombo F, Rodríguez M, Sacaliter H, Tarruella M, Yuma M, Cavallero E. Cardiovascular risk in supposedly healthy subjects. Rev Argent Endocrinol Metab. 2004;41:206-213.
22. Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol. 2005;174:827-834.
23. Mather KJ, Verma S, Anderson TJ. Improved endotelial function with metfomin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001;37:1344-1350.
24. Matthews DR, Hosker JP, Rudenski AS, Taylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
25. McCulloch DK, Campbell IW, Wu FC, Prescott RJ, Clarke BF. The prevalence of diabetic impotence. Diabetologia. 1980;18:279-283.
26. McFarlane S, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab. 2001;86:713-719.
27. Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT. Endogenous sex hormones and the metabolic syndrome in aging men. J Clin Endocrinol Metab. 2005;90: 2618-2623.
28. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV. Effects of diet and exercise in preventing NIIDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537-544.
29. Pitteloud N, Hardin M, Dwyer AA, Valassi E, Yialamas M, Elahi D, Hayes FJ. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab. 2005;90:2636-2641.
30. Rhoden EL, Telöken C, Sogari PR, Vargas Souto CA. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Imp Res. 2002;14:245-250.
31. Rosen R, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822-830.
32. Rosen RC, Capelleri JC, Smith MD, Lipsky J, Peña BM. Development and evaluation of an abridged, 5-item version of the international index of erectile function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Imp Res. 1999;11:319-326.
33. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007;92:405-413.
34. Sullivan ME, Thompson CS, Dashwood MR, Khan MA, Jeremy JY, Morgan RJ, Mikhailidis DP. Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease? Cardiovas Res. 1999;43:658-665.
35. Trussell JC, Legro RS. Erectile dysfunction: does insulin resistance play a part? Fertil Steril. 2007;88:771-777.
36. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:837-853.
37. Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet. 1985;1:181-184.
38. Vlachopoulos C, Ioakeimidis N, Terentes-Printzios D, Stefanadis C. The triad: erectile dysfunction-endothelial dysfunction-cardiovascular disease. Curr Pharm Des. 2008;14:3700-3714.
39. Walczak MK, Lokhandwala N, Hodge MB, Guay AT. Prevalence of cardiovascular risk factors in erectile dysfunction. J Gen Specif Med. 2002;5:19-24.